Company demonstrates excellent progress in its surgical aortic heart valve study SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that it has completed initial enrollment in its early feasibility study (EFS) for the Tria LifePolymer™ heart valve. Fifteen patients have been enrolled in […]
Tag: Foldax
Foldax Tria LifePolymer Heart Valve Technology Honored with Best Innovation Award at 2020 Cardiovascular Research Technologies Meeting
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that Tria LifePolymer™ heart valve technology was honored with The Best Innovation Award at the 2020 Cardiovascular Research Technologies (CRT) meeting in National Harbor, MD. The presentation, titled “Foldax Tria First in Human Implant […]
Foldax Tria LifePolymer Heart Valve Technology Honored with Best Innovation Award at 2020 Cardiovascular Research Technologies Meeting
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® announced today that Tria LifePolymer™ heart valve technology was honored with The Best Innovation Award at the 2020 Cardiovascular Research Technologies (CRT) meeting in National Harbor, MD. The presentation, titled “Foldax Tria First in Human Implant […]
Foldax®, Inc. Successfully Completes First-In-Human Use of Next-Generation Tria Polymer Heart Valve for the Treatment of Aortic Valve Disease
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for the treatment of aortic valve disease. Clinicians at Beaumont Hospital, Royal Oak, in Michigan, implanted this innovative […]
Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease. Using […]
Recent
BrioHealth Solutions Begins Patient Enrollment in INNOVATE Trial of BrioVAD® System for Advanced Heart Failure
Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data
Popular
- No commented posts yet